
We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Pharvaris NV is a clinical-stage company. It is focused on the discovery and development of novel oral bradykinin B2-receptor antagonists for the treatment of hereditary angioedema (HAE) and other bradykinin B2-receptor-mediated indications. Pharvaris NV is a clinical-stage company. It is focused on the discovery and development of novel oral bradykinin B2-receptor antagonists for the treatment of hereditary angioedema (HAE) and other bradykinin B2-receptor-mediated indications.
Period | Change | Change % | Open | High | Low | Avg. Daily Vol | VWAP | |
---|---|---|---|---|---|---|---|---|
1 | -0.275 | -1.79914949297 | 15.285 | 16.7499 | 14.14 | 69372 | 15.29655946 | CS |
4 | -2.8 | -15.7215047726 | 17.81 | 18.29 | 14.14 | 45370 | 16.13568333 | CS |
12 | -4.26 | -22.1069019201 | 19.27 | 20.48 | 14.14 | 45621 | 17.54151838 | CS |
26 | -4.05 | -21.2486883526 | 19.06 | 25.4985 | 14.14 | 76673 | 19.96370118 | CS |
52 | -10.59 | -41.3671875 | 25.6 | 27.464 | 14.14 | 73345 | 19.90009722 | CS |
156 | -2.44 | -13.9828080229 | 17.45 | 33 | 1.77 | 232902 | 12.67311715 | CS |
260 | -9.99 | -39.96 | 25 | 42.86 | 1.77 | 181899 | 13.45050639 | CS |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions